An observational study in Community-acquired Pneumonia, sponsored by Muğla Sıtkı Koçman University. Completed at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-04.
Sponsored by Muğla Sıtkı Koçman University · Observational
Despite the efficacy of modern treatment, community-acquired pneumonia (CAP) is the the leading cause of death. Prognostic scores have been developed to estimate the risk of adverse outcome. Several serum biomarkers have been also investigated in patients with CAP. A growing number of echocardiographic markers have been evaluated as possible predictors of prognosis in patients with pulmonary and infectious diseases such as sepsis, septic shock, human immunodeficiency virus infection, pulmonary tuberculosis, and chronic obstructive pulmonary disease. As echocardiography is a non-invasive, reliable, cost-effective, and reproducible diagnostic tool to evaluate cardiac function and structures, the investigators aimed to investigate left and right ventricular functions and aortic elastic properties in CAP patients. Furthermore, the investigators also aimed to observe relationships between echocardiographic findings and inflammatory and cardiac serum biomarkers in patients with CAP.
Despite the efficacy of modern treatment, community-acquired pneumonia (CAP) is the the leading cause of death. Prognostic scores, like the CURB-65 (confusion, urea, respiratory rate, arterial blood pressure and age) score and the pneumonia severity index (PSI) have been developed and validated to estimate the risk of adverse outcome and to register a patient with CAP for hospital admission. Serum biomarkers have been also investigated in patients with CAP like Procalcitonin and C-reactive protein. Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) has been shown to be associated with adverse prognosis in several cardiac conditions and critically ill patients. NT-proBNP is also shown to be important predictor in the emergency department and in hospitalized patients with CAP. A growing number of echocardiographic markers have been evaluated as possible predictors of prognosis in patients with pulmonary and infectious diseases such as sepsis, pulmonary tuberculosis, and chronic obstructive pulmonary disease. Although effects of pneumonia on cardiac structures is theoretically possible due to increased systemic inflammatory activity, prothrombotic conditions, biomechanical stress on coronary arteries, variations in coronary arterial tone, and altered myocardial metabolic balance during infections, the role of transthoracic echocardiography has never been evaluated in patients with CAP. As echocardiography is a non-invasive, reliable, cost-effective, and reproducible diagnostic tool to evaluate cardiac function and structures, the investigators aimed to investigate left and right ventricular functions and aortic elastic properties in CAP patients. Furthermore, the investigators also aimed to observe relationships between echocardiographic findings and inflammatory and cardiac serum biomarkers in patients with CAP.
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's enrollment of 210 is close to the median of 203 across 688 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Muğla Sıtkı Koçman University is the lead sponsor of 112 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pneumonia group is defined as patients with community acquired pneumonia diagnosis hospitalised through emergency department. The control group will be consisted of consecutive sex- and age-matched patients admitted to the emergency department.
Exclusion Criteria:
patients with community-acquired pneumonia
Device: echocardiography
patients admitted to emergency department with shortness of breath
Device: echocardiography
echocardiography: Left and right ventricular functions and aortic elastic properties.
the TAPSE value to discriminate patients with pneumonia
the TAPSE (Tricuspid annular plane systolic excursion ) value to discriminate patients with pneumonia
Time frame: 1 month
the BNP value to discriminate patients with pneumonia
the BNP (B-type natriuretic peptide) value to discriminate patients with pneumonia
Time frame: 1 month
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muğla Sıtkı Koçman University